• 1. New ester based gemini surfactants: the effect of different cationic headgroups on micellization properties and viscosity of aqueous micellar solution
  Avinash Bhadani,Misako Tani,Takeshi Endo,Kenichi Sakai,Masahiko Abe,Hideki Sakai Phys. Chem. Chem. Phys. 2015 17 19474

Recent Advances in the Application of Morpholine, 4-dodecyl- (CAS: 1541-81-7) in Chemical Biology and Pharmaceutical Research

The chemical compound Morpholine, 4-dodecyl- (CAS: 1541-81-7) has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This surfactant and phase-transfer agent, characterized by its amphiphilic nature, has been increasingly utilized in drug delivery systems, nanotechnology, and as a stabilizing agent in various formulations. Recent studies have explored its potential in enhancing the solubility and bioavailability of poorly water-soluble drugs, making it a critical component in modern pharmaceutical development.

A 2023 study published in the Journal of Medicinal Chemistry highlighted the role of Morpholine, 4-dodecyl- in improving the encapsulation efficiency of lipophilic drugs within micellar structures. The research demonstrated that the compound's unique ability to form stable micelles at low concentrations significantly enhances drug-loading capacity, thereby optimizing therapeutic efficacy. Furthermore, its biocompatibility and low toxicity profile make it an attractive candidate for in vivo applications.

In the realm of nanotechnology, Morpholine, 4-dodecyl- has been employed as a capping agent for the synthesis of gold and silver nanoparticles. A recent breakthrough published in ACS Nano revealed that the compound's long alkyl chain and morpholine ring facilitate the formation of uniformly sized nanoparticles with enhanced stability and controlled release properties. These nanoparticles have shown promise in targeted drug delivery and imaging applications, particularly in oncology.

Another area of interest is the compound's potential in antimicrobial formulations. A 2024 study in Antimicrobial Agents and Chemotherapy reported that Morpholine, 4-dodecyl- exhibits synergistic effects when combined with conventional antibiotics, significantly reducing the minimum inhibitory concentration (MIC) against multidrug-resistant bacterial strains. This finding opens new avenues for combating antibiotic resistance, a pressing global health challenge.

Despite its promising applications, challenges remain in the large-scale production and regulatory approval of formulations containing Morpholine, 4-dodecyl-. Recent efforts have focused on optimizing synthetic routes to improve yield and purity, as well as conducting comprehensive toxicological assessments to ensure safety. Collaborative research between academia and industry is expected to accelerate the translation of these findings into clinically viable products.

In conclusion, Morpholine, 4-dodecyl- (CAS: 1541-81-7) continues to be a molecule of significant interest in chemical biology and pharmaceutical research. Its multifunctional properties and broad applicability position it as a key player in the development of next-generation therapeutics and nanomedicines. Ongoing research is likely to uncover further innovative uses, solidifying its role in advancing biomedical science.

• 47034-41-3(4-dodecyl-4-ethylmorpholin-4-ium)
• 55717-07-2(4-icosylmorpholine)
• 13063-60-0(Morpholine, 4-octyl-)
• 25727-94-0(Morpholine, 4-decyl-)
• 25727-93-9(Morpholine,4-tetradecyl-)
• 2937-98-6(Morpholine, 4-pentyl-)
• 16528-77-1(4-Octadecylmorpholine)
• 25727-91-7(4-Hexadecylmorpholine)
• 5419-18-1(4-hexadecylmorpholine)
• 39793-32-3(5-(morpholin-4-yl)pentan-1-amine)